While BRAF and KRAS mutations both lead to activation of the RAS-RAF-MEK-cascade, KRAS mutations occur during tumour progression in the classical pathway or suppressor pathway while BRAF mutations are initiating mutations in the sessile serrated pathway (Nakanishi et al. 2019). The gene discussed is BRAF; the disease is neoplasm.